Agate Medical Investments

BrainsGate, Ltd. is a medical device company based in Caesarea, Israel, specializing in therapies for central nervous system diseases, particularly acute ischemic stroke. Founded in 2000, the company has developed a technology platform that utilizes electrical stimulation of the spheno-palatine ganglion (SPG) to enhance cerebral blood flow. Its innovative treatment approach involves a miniature electrode implanted in the roof of the mouth through a minimally invasive procedure performed under local anesthesia. BrainsGate's key product is an ischemic stroke system that delivers targeted stimulation to the SPG, with the aim of improving outcomes for stroke patients. The company has conducted significant clinical trials, including a pivotal study with 300 participants that demonstrated the safety and efficacy of its treatment. Currently, BrainsGate is advancing the ImpACT-24b trial, a multinational randomized study assessing the treatment's effectiveness within a critical 24-hour window following stroke onset.

CLEW Medical Ltd. is a healthcare technology company based in Netanya, Israel, specializing in predictive clinical analytics for intensive care units (ICUs). Founded in 2014, CLEW develops an analytics platform that utilizes existing ICU data to forecast life-threatening complications and detect patient deterioration in real-time. This platform provides healthcare providers and administrators with critical alerts and predictive warnings throughout a patient's ICU stay, enabling timely interventions and enhancing clinical outcomes. The company's advanced analytics engine employs innovative prediction models derived from Big Data analysis, allowing it to manage large patient populations while addressing individual treatment needs effectively. CLEW Medical aims to support healthcare institutions in improving patient care through its sophisticated analytics solutions.

Rapid Medical Ltd. is a medical device company specializing in neurovascular interventional treatments aimed at addressing ischemic and hemorrhagic strokes. Founded in 2008 and headquartered in Yokne'am Illit, Israel, the company develops innovative products such as the Tigertriever, a revascularization device; DRIVEWIRE, a steerable guidewire designed for complex anatomical navigation; and Comaneci, a controllable device for managing aneurysm necks. Rapid Medical is dedicated to enhancing patient care by delivering high-quality, reliable medical devices that are easy to use and supported by robust clinical data. The company has established a distribution network across several countries in Europe, as well as in India, reflecting its commitment to expanding access to its advanced medical technologies.

CLEW Medical Ltd. is a healthcare technology company based in Netanya, Israel, specializing in predictive clinical analytics for intensive care units (ICUs). Founded in 2014, CLEW develops an analytics platform that utilizes existing ICU data to forecast life-threatening complications and detect patient deterioration in real-time. This platform provides healthcare providers and administrators with critical alerts and predictive warnings throughout a patient's ICU stay, enabling timely interventions and enhancing clinical outcomes. The company's advanced analytics engine employs innovative prediction models derived from Big Data analysis, allowing it to manage large patient populations while addressing individual treatment needs effectively. CLEW Medical aims to support healthcare institutions in improving patient care through its sophisticated analytics solutions.

MST Medical Surgery Technologies Ltd., founded in 2005 and headquartered in Tel Aviv, Israel, with an additional office in Apollo Beach, Florida, specializes in developing advanced image analysis software for the healthcare industry. The company is a leader in surgical analytics, focusing on medical robotics and computer-assisted surgery. Its flagship product, AutoLap, is an innovative robotic image-guided laparoscope positioning system that enhances the precision and control of surgical procedures by providing real-time guidance based on the surgeon's movements. Additionally, MST offers Surgical Training Analytics (STA), a tool designed to capture images from actual surgical procedures, aiding in the training of new surgeons. By leveraging advanced visualization, artificial intelligence, and machine learning, MST aims to transform the operating room with automated, data-driven solutions that improve outcomes for both surgeons and patients.

DiA Imaging Analysis Ltd. is a technology company based in Beersheba, Israel, specializing in AI-powered ultrasound analysis designed to enhance the evaluation of cardiac function and other medical conditions. Founded in 2009, DiA offers a range of innovative applications, including LVivo EF for automated ejection fraction evaluation, LVivo RV for right ventricle analysis, and LVivo Strain, which assesses myocardial strain as an early indicator of reduced left ventricular function. Their tools simplify the ultrasound imaging process by providing automated analysis and optimal view selection, improving the diagnostic capabilities of clinicians. DiA's technology is compatible with various ultrasound devices and healthcare IT systems, streamlining the detection of clinical abnormalities. The company holds FDA and CE clearances and serves thousands of users globally, addressing critical challenges in ultrasound utilization by enabling more accurate and efficient image analysis through advanced pattern recognition and machine learning algorithms.

Angioslide, Ltd. is a medical device company established in 2005 and headquartered in Natanya, Israel, with additional subsidiaries in Karlsruhe, Germany, and Edina, Minnesota. The company specializes in developing innovative angioplasty products, notably the Angioslide eXtra balloon catheter, which serves both as a stand-alone balloon for angioplasty and as a device for debris removal. Its proprietary Embolic Capture Angioplasty™ technology allows physicians to capture and eliminate embolic particles, chronic thrombus, and atherosclerotic plaque debris during angioplasty procedures. Angioslide focuses on addressing the needs of various markets, including peripheral artery, lower limb artery, carotid, and coronary artery diseases.

Ornim, Inc. is a biomedical technology company specializing in the development and distribution of non-invasive medical monitoring tools for measuring blood flow and oxygen saturation in patients. Founded in 2004 and based in Santa Clarita, California, with a research and development subsidiary in Israel, Ornim has created innovative products such as the CerOx and c-FLOW monitors. These devices utilize patented UTLight technology, which combines light and ultrasound to deliver real-time, continuous measurements of cerebral blood flow and oxygen saturation. The CerOx monitor is unique in the market for its ability to measure both parameters simultaneously, while the c-FLOW focuses solely on cerebral blood flow. Ornim's solutions are designed to enhance individualized patient care by providing critical insights into blood flow variations, thereby enabling informed clinical interventions. The company holds numerous patents, reflecting its commitment to overcoming the limitations of existing monitoring technologies, and aims to improve treatment outcomes and reduce healthcare costs through its innovative monitoring solutions.

Peptron, Inc. is a biotechnology company based in Daejeon, South Korea, that specializes in the development of peptide-based medicines aimed at treating chronic and life-threatening diseases. Founded in 1997, Peptron focuses on creating long-acting therapies to address conditions such as neurodegenerative disorders, cancer, and endocrine-related diseases. The company utilizes its proprietary technologies, including SmartDepot, an advanced method for formulating sustained release injectable microspheres. Peptron's research and development pipeline includes several innovative products, such as Luphere Depot for prostate cancer and endometriosis, as well as formulations targeting acromegaly and type 2 diabetes. The company's commitment to integrating extensive peptide research and drug delivery technologies underlines its patient-focused approach to healthcare.

Angioslide, Ltd. is a medical device company established in 2005 and headquartered in Natanya, Israel, with additional subsidiaries in Karlsruhe, Germany, and Edina, Minnesota. The company specializes in developing innovative angioplasty products, notably the Angioslide eXtra balloon catheter, which serves both as a stand-alone balloon for angioplasty and as a device for debris removal. Its proprietary Embolic Capture Angioplasty™ technology allows physicians to capture and eliminate embolic particles, chronic thrombus, and atherosclerotic plaque debris during angioplasty procedures. Angioslide focuses on addressing the needs of various markets, including peripheral artery, lower limb artery, carotid, and coronary artery diseases.

Sensimed AG is a medical devices company based in Lausanne, Switzerland, founded in 2003. The company specializes in the design, development, and commercialization of integrated micro-systems for medical applications, particularly focusing on glaucoma management. Its flagship product, the SENSIMED Triggerfish, is a soft, single-use contact lens that enables continuous monitoring of intraocular pressure (IOP) fluctuations in glaucoma patients over a 24-hour period. The Triggerfish system includes disposable sensors, an adhesive antenna for communication, a battery-powered recorder for data collection, and software for data management and analysis. Sensimed aims to enhance personalized treatment for glaucoma patients by analyzing the collected data to identify pathological patterns and improve clinical outcomes. The company's products are distributed through partners across Europe, Asia-Pacific, the Middle East, and the Americas. As of December 2019, Sensimed operates as a subsidiary of SEED Co., Ltd.

EndoChoice is a medical device company specializing in the development and commercialization of technologies for gastrointestinal (GI) care. Founded in 2008 and headquartered in Alpharetta, Georgia, the company offers a range of products that include single-use devices, diagnostics, infection control products, and endoscopic imaging systems tailored for GI specialists. One of its notable innovations is the Full Spectrum Endoscopy™ System, which features colonoscopes and gastroscopes equipped with multiple imagers, allowing for a wider field of view compared to traditional endoscopes. This technology has demonstrated its efficacy by detecting significantly more polyps during colonoscopy procedures. EndoChoice serves over 2,000 customers in the United States and collaborates with 34 distribution partners globally. The company was recognized by Inc. Magazine as one of the fastest-growing companies in the U.S. for four consecutive years prior to its acquisition by Boston Scientific in 2016.

Valeritas Holdings, Inc. was a medical technology company focused on developing and commercializing innovative solutions for the treatment of Type 2 diabetes. Founded in 2006 and headquartered in Bridgewater, New Jersey, the company offered the V-Go, a wearable insulin delivery device designed for basal-bolus therapy, allowing patients to manage their insulin intake conveniently and discreetly. Valeritas was also working on additional products, including the V-Go Prefill, aimed at simplifying the device-filling process, and V-Go SIM, which would facilitate real-time tracking of dosing utilization. The company marketed its products through third-party wholesalers and medical supply distributors, aiming to enhance the health and quality of life for individuals living with diabetes. However, on June 30, 2020, Valeritas Holdings filed for Chapter 11 bankruptcy, leading to its cessation of operations.

Angioslide, Ltd. is a medical device company established in 2005 and headquartered in Natanya, Israel, with additional subsidiaries in Karlsruhe, Germany, and Edina, Minnesota. The company specializes in developing innovative angioplasty products, notably the Angioslide eXtra balloon catheter, which serves both as a stand-alone balloon for angioplasty and as a device for debris removal. Its proprietary Embolic Capture Angioplasty™ technology allows physicians to capture and eliminate embolic particles, chronic thrombus, and atherosclerotic plaque debris during angioplasty procedures. Angioslide focuses on addressing the needs of various markets, including peripheral artery, lower limb artery, carotid, and coronary artery diseases.

Lumenis Ltd. is a leading global developer and provider of energy-based medical systems tailored for minimally invasive procedures across various sectors, including surgical, ophthalmic, and aesthetic markets. Founded in 1991 and headquartered in Yokneam, Israel, Lumenis manufactures surgical laser systems utilized in urology and ENT, as well as ophthalmic laser systems designed for retinal treatment, glaucoma, and refractive applications. In the aesthetic realm, the company offers advanced laser technologies for skin treatments and hair removal. In addition to its product offerings, Lumenis provides comprehensive support services, including technical training, installation, maintenance, and access to spare parts. The company markets its products through a robust network of direct sales representatives and third-party distributors. Lumenis emphasizes the transformative power of light in enhancing life, reflecting its commitment to developing innovative solutions that improve medical and cosmetic outcomes.

Navotek Medical develops real-time innovative tracking and navigation solutions for medical applications. The first application is in the oncology field, providing tumor localization and tracking for optimal radiation therapy. Navotek’s solution will allow for safer and more effective treatment, improving the chances of tumor eradication and decreasing the rate of complications. In addition, it will potentially improve the efficiency of the treatment procedure by shortening individual sessions as well as entire treatment courses. This will increase the radiation rooms’ throughput which will translate into increased earnings for the hospital.

BrainsGate, Ltd. is a medical device company based in Caesarea, Israel, specializing in therapies for central nervous system diseases, particularly acute ischemic stroke. Founded in 2000, the company has developed a technology platform that utilizes electrical stimulation of the spheno-palatine ganglion (SPG) to enhance cerebral blood flow. Its innovative treatment approach involves a miniature electrode implanted in the roof of the mouth through a minimally invasive procedure performed under local anesthesia. BrainsGate's key product is an ischemic stroke system that delivers targeted stimulation to the SPG, with the aim of improving outcomes for stroke patients. The company has conducted significant clinical trials, including a pivotal study with 300 participants that demonstrated the safety and efficacy of its treatment. Currently, BrainsGate is advancing the ImpACT-24b trial, a multinational randomized study assessing the treatment's effectiveness within a critical 24-hour window following stroke onset.

Iscare specializes in assisted reproduction, complex treatment of obesity, gastroenterology, and treatment of idiopathic intestinal inflammations